上个月,美国FDA肿瘤药物咨询委员会以10:0的投票一致通过,批准诺华的CAR-T疗法CTL019用于治疗儿童、青少年复发或难治性B细胞ALL。这一成功标志着靶向细胞疗法发展的一个里程碑,并推动了针对其他肿瘤特异性抗原CAR-T疗法的发展和进步。
嵌合抗原受体T(CAR-T)细胞免疫疗法,简单来说,就是体外改造T细胞,使其表面表达特异性识别肿瘤表面抗原的受体片段,然后输入患者体内,不需要抗原递呈细胞(APC)的帮助,直接靶向体内癌细胞并发挥免疫杀伤作用。CAR-T技术经历不断优化,已经发展到成熟的第三代,即含有基本的胞外单链可变区片段(ScFv),胞内两个共刺激因子模块和CD3 ζ模块的T细胞。在被临床试验广泛证明有效性后,CAR-T疗法的安全性引起越来越多的关注,促进了第四代CAR-T技术的发展,各种降低CAR-T副作用的策略应运而生,比如双重靶点CAR、整合抑制调节因子的CAR、甚至整合自杀基因的CAR等。另外,在靶点选择方面,除了热度不减的CD19以外,更多类别的肿瘤细胞特别是实体瘤细胞表面特异性抗原被作为靶点被大力开发用于CAR-T细胞免疫疗法。
ACROBiosystems开发了一系列针对CAR-T的靶点蛋白,其中包括许多生物素预先标记的蛋白,这些生物素预先标记的蛋白适用于Biopanning来筛选ScFv, 以及后续筛选CAR表达的细胞。
BC7-H82F0 (Biotinylated Human BCMA)
BCA-H522Y(Human BCMA)
RO1-H821y (Biotinylated Human ROR1)
RO1-H522y (Human ROR1)
CD3-H82E7 (Biotinylated Human CD33)
CD3-H5226 (Human CD33)
EGR-H82E0 (Biotinylated Human EGFRVIII)
EGI-H52H4 (Human EGFRvIII)
CD0-H82E6 (Biotinylated Human CD30)
CD0-H5229 (Human CD30)
EGR-H82E3 (Biotinylated Human EGFR)
EGR-H5222 (Human EGFR)
FO1-M82E9 (Biotinylated Mouse FOLR1)
FO1-H5229 (Human FOLR1)
HE2-H822R (Biotinylated Human Her2)
HE2-H5225 (Human Her2)
MET-H82E1 (Biotinylated Human HGF R)
MET-H5227 (Human HGF R)
CD9-H8259 (Biotinylated Human CD19)
CD9-H5226 (Human CD19 (20-291))
CD0-H5268 (Human MS4A1 / CD20, Fc Tag)
Biotinylated product is coming soon
EPM-H82E8 (Biotinylated Human EpCAM)
EPM-H5223 (Human EpCAM)
GP3-H5223 (Human Glypican 3)
Biotinylated product is coming soon.
MSN-H82E9 (Biotinylated Human MSLN)
MSN-H5223 (Human MSLN)
CD8-H82E7 (Biotinylated Human CD38)
CD8-H5224 (Human CD38)
靶点
适应症
推荐产品
BCMA
多发性骨髓瘤、白血病、B细胞淋巴瘤
ROR1
白血病、乳腺癌
CD33
急性髓系白血病
EGFRVIII
胶质母细胞瘤
CD30
白血病、B细胞淋巴瘤
EGFR
非小细胞肺癌、上皮癌、胶质瘤
FOLR1
卵巢癌
HER2
卵巢癌、乳腺癌、胶质母细胞瘤、骨肉瘤
c-MET/HGFR
恶性黑色素瘤、乳腺癌
CAIX
肾细胞癌
CA9-H5226 (Human CA9 (38-414))
CD19
急性白血病、B细胞淋巴瘤
CD20
白血病、B细胞淋巴瘤
EpCAM
肝肿瘤、胃肿瘤
GPC3
原发性肝细胞癌
IL-13 R alpha 2
胶质瘤
IL2-H5257 (Human IL13Rα2, Fc Tag)
MSLN
间皮瘤、卵巢癌
MUC1
精囊癌
MU1-H5252 (Human MUC-1, Fc Tag)
CD138
多发性骨髓瘤
SD1-H5228 (Human Syndecan-1 / CD138)
CD38
B细胞恶性肿瘤
Claudin18.2
胃癌
Products are coming soon.
部分与抗体结合ELISA实验如下:
Immobilized Human Her2, His Tag (Cat. No. HE2-H5225) at 0.05 μg/mL (100 μL/well) can bind Trastuzumab with a linear range of 0.2-3 ng/mL.
Immobilized CetuxiMabat 2 μg/mL (100 μL/well) can bind Biotinylated Human EGFRvIII (Cat. No. EGR-H82E0) with a linear range of 0.4-25 ng/mL.
Immobilized Anti-CD30 MAb, Human IgG1 at 5 μg/mL (100 μL/well) can bind Biotinylated Human CD30, His Tag (Cat. No. CD0-H82E6) with a linear range of 0.4-6.5 ng/mL.
Immobilized anti human CD33 MAb, Mouse IgG1 (Clone # 6C5/2) at 2 μg/mL (100 μL/well) can bind Biotinylated Human Siglec-3, His Tag (Cat. No. CD3-H82E7) with a linear range of 0.078-2.5 ng/mL.
ACROBiosystems百普赛斯生物科技股份有限公司
北京:010-53681107
上海:021-50850665
邮箱:(产品订购)order.cn@acrobiosystems.com
邮箱:(技术支持)tech.cn@acrobiosystems.com
邮箱:(廉洁合规)lianjie@acrobiosystems.com
地址:北京经济技术开发区宏达北路8号5号楼4层